{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-044400","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.150004+00:00","generated_at":"2026-06-07T15:07:59.915815+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ZyVersa Therapeutics prices $5.0M public offering of common stock and warrants","bullets":["Offering of 4M shares (or pre-funded warrants in lieu) plus 4M Series A and 4M Series B warrants at combined $1.25 per unit.","Gross proceeds ~$5.0M; net proceeds for working capital and general corporate purposes.","Series A warrants $1.25 strike, 5-year term; Series B warrants $1.25 strike, 18-month term, both immediately exercisable.","Offering closed on December 11, 2023; A.G.P./Alliance Global Partners acted as sole placement agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-044400","json":"https://secwatch.observer/filing/0001493152-23-044400.json","markdown":"https://secwatch.observer/filing/0001493152-23-044400.md","text":"https://secwatch.observer/filing/0001493152-23-044400.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/0001493152-23-044400-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:07:59.915815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"979b97baa6b8b06d5847ae3aca9c1651e8c81ca9","claim":"ZyVersa Therapeutics, Inc. entered into Securities Purchase Agreement with purchasers identified on the signature pages valued at 400,000 shares of common stock, pre-funded warrants for 3,600,000 shares, Series A common warrants f (effective 2023-12-06).","evidence_excerpt":"On December 6, 2023, ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement with each purchaser identified on the signature pages thereto (the “Purchase Agreement”), pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), (i) 400,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 3,600,000 pre-funded warrants (the “Pre-Funded Warrants”) exercisable for an aggregate of 3,600,000 shares of Common Stock, (iii) 4,000,000 Series A common warrants (the “Series A Common Warrants”) exercisable for an aggregate of 4,000,000 shares of Common Stock, and (iv) 4,000,000 Series B common warrants (the “Series B Common Warrants,” and together with the Series A Common Warrants, the “Common Warrants”) exercisable for an aggregate of 4,000,000 shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/0001493152-23-044400-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"purchasers identified on the signature pages"},{"label":"Value","value":"400,000 shares of common stock, pre-funded warrants for 3,600,000 shares, Series A common warrants f"},{"label":"Effective","value":"2023-12-06"}],"fact_type":"material_agreement"},{"claim_id":"f9c42dbf8d268d8941a50664a08ade82668c231e","claim":"ZyVersa Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to 6.0% of gross proceeds, expense reimbursement up to $80,000, non-accountable expen (effective 2023-12-06).","evidence_excerpt":"On December 6, 2023, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which A.G.P. agreed to act as exclusive placement agent for the issuance and sale of the Shares and Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223044400/0001493152-23-044400-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"cash fee equal to 6.0% of gross proceeds, expense reimbursement up to $80,000, non-accountable expen"},{"label":"Effective","value":"2023-12-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}